BACKGROUND: Pulse pressure (an indirect measure of arterial stiffness) is a robust predictor of cardiovascular events, but its pathophysiology remains poorly understood. To gain insight into the pathophysiology of arterial stiffness we conducted an exploratory investigation of the associations of 47 circulating biomarkers in etiologic pathways of arteriosclerosis with brachial artery pulse pressure. METHODS: Participants included 1,193 African-Americans and 1,145 non-Hispanic whites belonging to hypertensive sibships. Blood pressure (BP) was measured with a random-zero sphygmomanometer. Multivariable linear regression was employed to assess the associations of biomarkers with pulse pressure after adjustment for age, sex, conventional risk factors, mean arterial pressure, heart rate, and use of aspirin, statins, estrogens, and antihypertensives. Statistical significance was set at P ≤ 0.001 (Bonferroni correction for multiple testing). RESULTS: Log N-terminal probrain natriuretic peptide (NT-proBNP) (African-Americans: β = 2.11 ± 0.52, non-Hispanic whites: β = 2.65 ± 0.55), log midregional proatrial natriuretic peptide (African-Americans: β = 4.83 ± 0.70, non-Hispanic whites: β = 3.70 ± 0.67), and log osteoprotegerin (African-Americans: β = 4.64 ± 1.02, non-Hispanic whites: β = 4.19 ± 0.99) were independently associated with pulse pressure (P < 0.001 for all) in both ethnicities. Log C-reactive protein (CRP) (β = 1.56 ± 0.35), log midregional proadrenomedullin (MR-proADM) (β = 5.53 ± 1.19) and log matrix metalloproteinase-2 (β = 3.89 ± 1.06) were associated with greater pulse pressure in African-Americans only (P ≤ 0.001 for all), whereas higher fibrinogen was associated with pulse pressure in non-Hispanic whites only (β = 0.02 ± 0.004. P < 0.001). CONCLUSIONS: Our results suggest that hemodynamic stress, vascular inflammation and calcification, and matrix remodeling may have a role in the pathogenesis and/or adverse consequences of increased pulse pressure.
BACKGROUND: Pulse pressure (an indirect measure of arterial stiffness) is a robust predictor of cardiovascular events, but its pathophysiology remains poorly understood. To gain insight into the pathophysiology of arterial stiffness we conducted an exploratory investigation of the associations of 47 circulating biomarkers in etiologic pathways of arteriosclerosis with brachial artery pulse pressure. METHODS:Participants included 1,193 African-Americans and 1,145 non-Hispanic whites belonging to hypertensive sibships. Blood pressure (BP) was measured with a random-zero sphygmomanometer. Multivariable linear regression was employed to assess the associations of biomarkers with pulse pressure after adjustment for age, sex, conventional risk factors, mean arterial pressure, heart rate, and use of aspirin, statins, estrogens, and antihypertensives. Statistical significance was set at P ≤ 0.001 (Bonferroni correction for multiple testing). RESULTS: Log N-terminal probrain natriuretic peptide (NT-proBNP) (African-Americans: β = 2.11 ± 0.52, non-Hispanic whites: β = 2.65 ± 0.55), log midregional proatrial natriuretic peptide (African-Americans: β = 4.83 ± 0.70, non-Hispanic whites: β = 3.70 ± 0.67), and log osteoprotegerin (African-Americans: β = 4.64 ± 1.02, non-Hispanic whites: β = 4.19 ± 0.99) were independently associated with pulse pressure (P < 0.001 for all) in both ethnicities. Log C-reactive protein (CRP) (β = 1.56 ± 0.35), log midregional proadrenomedullin (MR-proADM) (β = 5.53 ± 1.19) and log matrix metalloproteinase-2 (β = 3.89 ± 1.06) were associated with greater pulse pressure in African-Americans only (P ≤ 0.001 for all), whereas higher fibrinogen was associated with pulse pressure in non-Hispanic whites only (β = 0.02 ± 0.004. P < 0.001). CONCLUSIONS: Our results suggest that hemodynamic stress, vascular inflammation and calcification, and matrix remodeling may have a role in the pathogenesis and/or adverse consequences of increased pulse pressure.
Authors: N Bucay; I Sarosi; C R Dunstan; S Morony; J Tarpley; C Capparelli; S Scully; H L Tan; W Xu; D L Lacey; W J Boyle; W S Simonet Journal: Genes Dev Date: 1998-05-01 Impact factor: 11.361
Authors: Iftikhar J Kullo; James B Seward; Kent R Bailey; Lawrence F Bielak; Brandon R Grossardt; Patrick F Sheedy; Patricia A Peyser; Stephen T Turner Journal: Am J Hypertens Date: 2005-08 Impact factor: 2.689
Authors: Charlotte A Keyzer; Martin H de Borst; Else van den Berg; Willi Jahnen-Dechent; Spyridon Arampatzis; Stefan Farese; Ivo P Bergmann; Jürgen Floege; Gerjan Navis; Stephan J L Bakker; Harry van Goor; Ute Eisenberger; Andreas Pasch Journal: J Am Soc Nephrol Date: 2015-04-29 Impact factor: 10.121
Authors: Alfonso Eirin; Xiang-Yang Zhu; John R Woollard; Sandra M Herrmann; Monika L Gloviczki; Ahmed Saad; Luis A Juncos; David A Calhoun; Andrew D Rule; Amir Lerman; Stephen C Textor; Lilach O Lerman Journal: Hypertension Date: 2013-06-24 Impact factor: 10.190
Authors: Aaron R Folsom; Lu Yao; Alvaro Alonso; Pamela L Lutsey; Emil Missov; Frank A Lederle; Christie M Ballantyne; Weihong Tang Journal: Circulation Date: 2015-06-17 Impact factor: 29.690
Authors: Farzin Beygui; Philipp S Wild; Tanja Zeller; Marine Germain; Raphaele Castagné; Karl J Lackner; Thomas Münzel; Gilles Montalescot; Gary F Mitchell; Germaine C Verwoert; Kirill V Tarasov; David-Alexandre Trégouët; François Cambien; Stefan Blankenberg; Laurence Tiret Journal: Circ Cardiovasc Genet Date: 2014-07-22
Authors: Stijn A Peeters; Lian Engelen; Jacqueline Buijs; Nish Chaturvedi; John H Fuller; Anders Jorsal; Hans-Henrik Parving; Lise Tarnow; Simone Theilade; Peter Rossing; Casper G Schalkwijk; Coen D A Stehouwer Journal: Cardiovasc Diabetol Date: 2017-10-25 Impact factor: 9.951